Cloud-Clone expands low-passage mesenchymal stem cell portfolio for research

Cloud-Clone says its low-passage mesenchymal stem cells are built for degenerative disease research, cell therapy development and preclinical studies across multiple species. The company is pairing the products with custom isolation, culture media and CRO services to support end-to-end workflows.

Why it matters: - Low-passage mesenchymal stem cells can help researchers study disease mechanisms and test regenerative approaches with more biologically relevant cells than immortalized lines. - Cloud-Clone is positioning the products for drug screening, tissue regeneration, degenerative disease models and preclinical cell-therapy work. - The company also says the platform is designed to reduce common research bottlenecks, including limited supply, batch inconsistency and low post-thaw viability.

What happened: - Cloud-Clone said it has completed a full development cycle for primary cell products, including premium primary mesenchymal stem cells, through its in-house animal facility. - The company released a portfolio of low-passage MSCs derived from umbilical cord, placenta, bone marrow, adipose tissue and synovium. - Cloud-Clone also highlighted related research support services, including custom cell isolation, MSC-specific culture medium and CRO experimental services. - More information is available on Cloud-Clone's website.

The details: - Cloud-Clone says its primary cells come from fresh living tissues and retain native gene expression and physiological function more closely than immortalized cell lines. - The company says its in-house animal center covers nearly 1,000 m² and operates under SPF standards with traceable animal strains and genetic information. - Cloud-Clone says it has developed custom culture systems for more than 560 conventional primary cell types, including cardiomyocytes, neurons, hepatocytes and epithelial cells. - The portfolio covers human, mouse, rat, rabbit, dog, cat, pig and guinea pig products. - The company says its low-passage MSCs can be passaged for up to 10 generations while maintaining consistent karyotypes. - Cloud-Clone says post-thaw viability stays above 85%. - The company says the cells express CD73, CD90, CD105, CD29 and CD44, and do not express CD34, CD45, CD19 or HLA-DR. - Cloud-Clone says the cells support standard large-scale preparation, cryopreserved cell banking and both off-the-shelf and custom production. - The company says the cells can be induced to become osteoblasts, chondrocytes, myocytes, adipocytes and vascular endothelial cells. - Cloud-Clone says the MSCs secrete cytokines, antioxidant proteins and exosomes that support anti-inflammatory, pro-angiogenic and anti-apoptotic research. - The company says the low HLA-DR profile gives the cells low immunogenicity for allogeneic research across species. - Cloud-Clone says customized isolation can be built around animal age, strain and pathological model, including specimens from heart-failure guinea pigs and diabetic rats. - The company says its MSC-specific complete medium is designed to support proliferation, expansion and stemness maintenance. - Cloud-Clone says its CRO services cover transplantation, animal disease modeling, drug intervention, pathology and molecular validation.

Between the lines: - Cloud-Clone is presenting MSCs as a broader platform, not just a cell product, by linking the cells to culture media, banking and CRO execution. - The emphasis on multiple species and tissue sources suggests the company is targeting translational research teams that need flexible in vivo and preclinical models. - The messaging also reflects a push to move from basic cell supply toward higher-value research infrastructure.

What's next: - Cloud-Clone says researchers can use its full workflow to move from cell supply to data analysis and final research reports. - The company is likely to continue leaning on low-passage MSCs as a core offering for degenerative disease and cell-therapy research. - Cloud-Clone can be reached at 001-832-538-0970 or 0086-27-8425-9552, or by email at mail@cloud-clone.com and sales@cloud-clone.us. - The company also lists social channels on LinkedIn, Instagram, TikTok and X.

The bottom line: - Cloud-Clone is trying to turn low-passage MSCs into a one-stop research platform for scientists working on regenerative medicine and degenerative disease.